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A B S T R A C TObjectives: Omalizumab improves health outcomes for patients with
severe asthma. The purpose of this study was to conduct a cost-utility
analysis of omalizumab from a societal perspective by using the results
from a randomized controlled trial in Japan, and explore the efficient
use of omalizumab. Methods: We developed a Markov model to
compare omalizumab add-on therapy with standard therapy. Patients
transitioned between symptom-free, day-to-day, and exacerbation
states. Our model had a lifetime horizon in which 5-year omalizumab
add-on therapy was followed by standard therapy. Preference-based
utilities were extracted from another study. We estimated the expected
value of perfect information for patients’ response to omalizumab.
Results: In the base case, incremental cost-effectiveness ratio (ICER) for
omalizumab add-on therapy was US $755,200 (95% credible interval [CI]
$614,200–$1,298,500) per quality-adjusted life-year gained, compared
with standard therapy alone. One-way sensitivity analyses indicated
that the results were sensitive to asthma-related mortality, exacerbationsee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.01.007
st: The authors have indicated that they have no
-y@umin.net.
ondence to: Yuichi Imanaka, Department of Hea
Medicine, Yoshida Konoe-cho, Sakyo-ku, Kyoto 60risk, and omalizumab cost. The ICER for a responder subgroup was 22%
lower than that in the base case. Individual and population expected
value of perfect informations for the response were $4100 (95% CI
$2500–$6000) and $28 million (95% CI $17 million–$42 million) per year,
respectively. Conclusions: With a willingness-to-pay of $45,000 per
quality-adjusted life-year, omalizumab was not cost-effective in Japan.
Confining omalizumab therapy to previously predicted responders,
however, may be a reasonable strategy to reduce the ICER, as the cost-
effectiveness was observed to improve for these patients. Further
studies should be conducted to explore responder prediction methods.
Decreasing the price of omalizumab would improve cost-effectiveness.
Keywords: costs and benefits, decision making, economic evaluation,
pharmacoeconomics, value of information.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
With an estimated 300 million patients worldwide, asthma is a
common chronic disease that is recognized as a global public
health problem [1]. Clinical features of asthma in most patients
are well controlled with inhaled corticosteroids (ICS) via their
anti-inflammatory effects, whereas persistent asthma in some
patients is difficult to control with standard medications, includ-
ing ICS, and is designated severe asthma [2]. Patients with severe
asthma are obliged to decrease their health-related quality of life
(HRQOL), visit emergency departments, and become hospitalized.
Omalizumab is a recombinant humanized monoclonal anti-
IgE antibody that binds to IgE and inhibits its interaction with the
IgE receptor. Many clinical trials have shown that omalizumab
reduces exacerbation risk and improves HRQOL related to
asthma [3–6]. Omalizumab, however, is an expensive medication
(US $1874 per 4 weeks on average). Several economic evaluation
studies have been published [7–11]. Some of the findings from
these studies have been unfavorable for omalizumab, whereas
others have indicated the cost-effectiveness of omalizumab inpatients with a history of severe exacerbations and hospitaliza-
tion. The National Institute for Health and Clinical Excellence has
recommended omalizumab as an add-on therapy with optimized
standard therapy only in adults and adolescents with severe
asthma and recurrent severe exacerbations [12].
Omalizumab is making a growing contribution to the treat-
ment of severe asthma worldwide as an increasingly used
therapeutic modality [5,6]. What is needed to increase the cost-
effectiveness of omalizumab? One measure may be to develop
prediction methods for patients’ response to omalizumab ahead
of omalizumab therapy. Omalizumab has been reported to
provide different benefits for patients with severe asthma [3,4],
although a prediction method for identifying responders has not
been developed [5,6]. Predicting the response can contribute to
minimizing unnecessary drug exposure and health care costs for
nonresponders, who do not adequately respond to the therapy.
Previous studies and National Institute for Health and Clinical
Excellence recommendations have been based on clinical data
from large studies performed in many countries, excluding Asian
countries. The first randomized controlled trial (RCT) thatSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Japan [13,14]. Patients with severe asthma constitute a major
burden on the Japanese health care system due to their high
requirements for inpatient care [1]. Japan’s medical fees for
health care services are relatively low among Organisation for
Economic Co-operation and Development countries [15]. The
price of omalizumab differs among different studies ($635 in
our study, $489 [7], $522 [8], $562 [9], $568 [10], and $433 [11] per a
150-mg vial). These facts beg the question of whether omalizu-
mab is cost-effective in the Japanese setting.
The aims of this study were to assess the cost-effectiveness of
omalizumab in Japan by using clinical data from the RCTand cost
data, and to explore the efficient use of omalizumab.Methods
Our cost-utility analysis was performed from the societal per-
spective. The benefits of omalizumab, including effects on
HRQOL, exacerbation risk, and mortality risk, were expressed as
quality-adjusted life-years (QALYs) gained. The cost-effectiveness
of omalizumab was expressed as an incremental cost-
effectiveness ratio (ICER): omalizumab plus standard therapy
(the omalizumab add-on group) versus placebo plus standard
therapy (the standard therapy group). Standard therapy refers to
treatments recommended prior to omalizumab therapy in the
international clinical practice guidelines for the management of
adult asthma [16]. Treatment was considered cost-effective if the
ICER was below $45,000 (f5 million) per QALY gained [17]. Costs
and benefits were discounted at 3% per annum. All costs were
expressed as US dollars using the purchasing power parity rate
for Japanese yen and European euro to US dollars in 2010 (f111 ¼
$1, h0.805 ¼ $1) from the Organisation for Economic Co-operation
and Development National Accounts database. The models were
developed by using TreeAge Pro 2009 Healthcare (TreeAge Soft-
ware, Inc., Williamstown, MA).
Model Development
We developed a multistate transition model, or Markov model.
The model structure was based on the following four states:
symptom-free asthma, day-to-day asthma, asthma-related
exacerbation, and death (Fig. 1). Symptom-free and day-to-day
states were defined as no symptoms and relatively minor symp-
toms during the week, respectively. The exacerbation state wasig. 1 – Markov model structure for economic evaluation of
malizumab.split into three mutually exclusive categories: mild exacerbation,
severe exacerbation, and hospitalization. Mild exacerbation was
defined as relatively major symptoms during the week. Severe
exacerbation was defined as requiring treatment with systemic
corticosteroids. We linked the hospitalization state with asthma-
related death state. In previous economic evaluations of omali-
zumab [7–9], similar Markov models were used to evaluate the
cost-effectiveness of omalizumab add-on therapy. We added
the symptom-free state to the model used in previous studies
so as to fit our model to end points that were assessed in the RCT
in Japan.
The model cycle length was 1 week. The model had a lifetime
horizon in which 5-year omalizumab add-on therapy was fol-
lowed by standard therapy alone. The 5-year treatment duration
was selected because of its use in previous studies [7–9], and
represents a ‘‘compromise between the observed treatment
duration in trials and the increased assumptions and uncertainty
associated with the costs and outcomes of lifelong treatment’’ [9].
The study cohort matched the RCT population with an average
age of 50 years and 50% men.
Clinical Input
We used clinical data from the intention-to-treat population of
the RCT in Japan [13,14]. The RCT was a randomized, placebo-
controlled, double-blinded, multicenter study. Omalizumab was
evaluated for a 16-week treatment phase in 315 patients, aged
20 to 75 years, with moderate-to-severe persistent asthma
despite high-dose ICS and other controller medications. The
RCT assessed the number of symptom-free weeks, mild exacer-
bation weeks, severe exacerbation weeks, and hospitalizations
for each patient. The RCT measured asthma symptom scores,
which were a sum of exacerbation (range 3–9), wheezing (1),
and cough (range 0.5–1) scores, with a score of 0 denoting no
symptoms. Symptom-free weeks were defined as a total symp-
tom score of 0 during the week. Mild exacerbation and severe
exacerbation were defined as experiencing major symptoms to
some degree and requiring systemic corticosteroids, respectively.
The number of exacerbation weeks experienced by patients
was published for each treatment group. Rates were calculated as
per person-week. Rate ratios were calculated as the ratio of the
omalizumab add-on group compared with the standard therapy
group. Transition probabilities were obtained with the following
formula: 1  exp(rate).
The incidence of serious adverse effects, such as anaphylaxis,
was rare and similar in patients treated with omalizumab and
placebo [13,14]. The same was reported for a large multicountry
study [3]. Therefore, we did not incorporate any adverse effect costs
or utility decrements for either treatment group into our model.
Response to Omalizumab
Patients with severe asthma derive different benefits from oma-
lizumab [3,4]. It is difficult to predict the extent of benefits
derived by various patients based on pretreatment characteristics
[5,6]. Responders are identified by physicians’ global evaluation of
treatment effectiveness after 16-week omalizumab therapy [5,6].
Omalizumab add-on therapy is discontinued at 16 weeks in
nonresponders [5,6,12]. In our model, nonresponders reverted to
standard therapy alone after the termination of omalizumab add-
on therapy at 16 weeks. Responders were not identified in the
RCT in Japan. We incorporated a response rate of 60.5% into our
model [3,4].
Primary Utility Estimate
Because of the lack of detailed HRQOL measures in the RCT, we
derived preference-based utility values from one previous study
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 9 – 3 6 31[18], which reported utility values of asthma control levels (good,
mildly reduced, moderately reduced, and poor control) using the
EuroQol five-dimensional questionnaire index. Although the
asthma control levels described by this previous study [18] did
not perfectly fit our model, we regarded symptom-free, day-to-
day, and mild exacerbation states as ‘‘good control,’’ ‘‘mildly
reduced control,’’ and ‘‘moderately reduced control,’’ respectively,
and severe exacerbation and hospitalization states as ‘‘poor
control’’ for the purpose of utility estimates.
Alternative Utility Estimate
To examine the impact of utility estimates on the results, we
conducted additional analyses by using another set of utility
values reported by another previous study [19], which examined
utilities associated with asthma exacerbations by using a visual
analogue scale. We regarded day-to-day and mild exacerbation
states as ‘‘current asthma state’’ and ‘‘mild exacerbation,’’ respec-
tively, and severe exacerbation and hospitalization states as
‘‘severe exacerbation.’’ This previous study did not examine
values for the symptom-free state. We made an arbitrary and
extreme assumption that the utility value for patients in the
symptom-free state was 1. This assumption created a bias in
favor of omalizumab because patients in the omalizumab add-on
group were more likely to be in the symptom-free state than in
the standard therapy group.
Mortality
No fatalities were recorded in the RCT [13,14]. Our model,
however, included asthma-related death and death from other
causes because the Asthma Policy Model included both types of
death [20]. We calculated asthma-related mortality risk among
hospitalized asthmatic patients by using Japan’s official data-
bases [21,22]. Age-specific risk of death from other causes was
based on Japan’s vital statistics [22].
Cost Input
Direct health care costs of omalizumab, standard therapy, and
health care resource use for exacerbation and direct non–health
care costs of transportation were included in our model. These
unit costs were obtained from Japan’s official database [23] and
our department’s Quality Indicator/Improvement Project, which
collects clinical and claims data from more than 200 hospitals in
Japan. Productivity loss cost of survivors and deceased patients
was not included in the model.
Omalizumab is administered by subcutaneous injection. An
approximate dose is defined according to each patient’s body
weight and serum IgE level. Patients receive 75 mg, 150 mg, 225
mg, 300 mg, or 375 mg of omalizumab every 2 or 4 weeks. Mean
dose and mean number of 150-mg vials per patient per 4 weeks
were 398 mg and 2.95 vials, respectively, based on the dose
distributions observed in the RCT [14].
In Japan, omalizumab is wasteful for some patients in terms
of product content. For example, a patient who is administered
225 mg of omalizumab every 2 weeks requires four 150-mg vials
per 4 weeks. This is because an omalizumab vial is for single use
only; any remaining unused content is discarded. If 75-mg vials
were available, the patient in the above example would require
six 75-mg vials per 4 weeks. In the sensitivity analysis, we
assumed that the 75-mg vial would be developed and approved
in Japan and that the price of a 75-mg vial would be half the price
of a 150-mg vial.
To obtain standard therapy costs, we assumed that standard
therapy consisted of high-dose ICS, long-acting beta agonists,
theophylline, and leukotriene antagonists, which are all recom-
mended prior to omalizumab therapy in the international clinicalpractice guidelines [16]. As a combination therapy of high-dose
ICS and long-acting beta agonist, we considered the salmeterol/
fluticasone combination (500 mg, one puff twice daily) for the
base-case analysis and the budesonide/formoterol combination
(160 mg, four puffs twice daily) for the sensitivity analysis.
The omalizumab add-on group as well as the standard therapy
group incurred standard therapy costs. We did not consider
generic drugs.
We assumed that a patient in a severe exacerbation state made
one visit to the emergency department and that emergency depart-
ment visits and hospitalizations required transportation costs.
Sensitivity Analysis
We performed probabilistic sensitivity analysis with 5000 Monte
Carlo simulations to obtain 95% credible intervals (CIs) for outputs
of the model. We also performed one-way sensitivity analyses to
estimate the impact of the range (95% confidence interval) of rate
ratios (but not going above or below 1), utility values, omalizumab
cost, and our assumptions on the results. To estimate the impact
of utility values, we ran utilities over an arbitrary range from 10%
above to 10% below each value (but not going above 1) by using
the primary utility set. We also evaluated the following scenarios:
different asthma-related mortality, different standard therapy
cost, different unit cost of emergency department visit, different
unit cost of hospitalization, different transportation cost, and
different discount rate. We conducted a threshold analysis to
provide the break-even price of omalizumab for the base case. In
addition, we performed a subgroup analysis in which the target
population was assumed to suffer from particularly severe
asthma, with exacerbations rate double that of the base case
and a symptom-free rate half that of the base case.
The Value of Information Analysis
The expected value of perfect information (EVPI) is the price that
the health care system would be willing to pay to conduct further
research and gain access to perfect information because perfect
information can eliminate the possibility of making a wrong
decision based on existing (prior) information [24]. Administering
omalizumab to nonselective patients leads to the treatment of
nonresponders, which results in wasteful health care expendi-
ture. Prediction methods for the identification of responders
ahead of omalizumab treatment would help physicians avoid
the unnecessary treatment of nonresponders.
The ICER of omalizumab add-on therapy in the responder
subgroup relative to the standard therapy group was calculated
by subgroup analysis. The responder subgroup was entirely
composed of responders receiving 5-year omalizumab therapy.
Clinical outcomes for the responders were further improved
when compared with the total number of patients treated with
omalizumab [3,4]. The clinical parameters of responders from the
large multicountry study were incorporated into our model
[5,25,26].
We estimated the individual EVPI for the omalizumab
response from the difference in net monetary benefits between
the omalizumab add-on group (i.e., the total number of patients
treated with omalizumab) and the responder subgroup. We then
calculated the population EVPI per year for the total number of
expected patients in Japan by multiplying the individual EVPI
(minus screening costs for each patient) by the incidence of
eligible patients, which was estimated from the incidence of
adult asthma (3.6/1000 and 4.6/1000 person-year in men and
women, respectively) [27] and the proportion of severe asthma
(1.6%) [28]. We assumed that the screening test for each patient
cost $180, which is similar to the cost of gene mutation testing
in Japan.
Table 1 – Clinical inputs and cost inputs in our economic model.
Standard
therapy group
Omalizumab add-on group Responder subgroupy Source
Rate per person-week and risk ratio
Symptom-free rate 0.16 RR 1.68 (95% CI 1.48–1.91) RR 2.03 (95% CI 1.49–2.81) [13,14,25]
Mild exacerbation rate 0.067 RR 0.55 (95% CI 0.43–0.71) RR 0.40 (95% CI 0.29–0.55) [5,13,14,26]
Severe exacerbation rate 0.0069 RR 0.36 (95% CI 0.14–0.91) RR 0.24 (95% CI 0.12–0.50) [5,13,14,26]
Hospitalization rate 0.0015 RR 0.27 (95% CI 0.03–2.43) RR 0.24 (95% CI 0.13–0.42) [5,13,14,26]
Utility for initial and reproducibility analysesz
Symptom-free asthma 0.93 (1) [18] and assumption
Day-to-day asthma 0.76 (0.81) [18,19]
Mild exacerbation 0.65 (0.62) [18,19]
Severe exacerbation 0.52 (0.26) [18,19]
Hospitalization 0.52 (0.26) [18,19]
Mortality
Risk of death from asthma given a hospitalization 0.0155 [21,22]
Proportion of responders 60.5% 100% [3,4]
Direct cost ($)
Standard therapy cost per 4 wk for base case 147 Model case
Standard therapy cost per 4 wk for sensitivity analysis 274 Model case
Omalizumab cost per 4 wk, using 150-mg vial ($635/vial) 1874 [13,14]
Omalizumab cost per 4 wk, using 75-mg vial ($318/vial)§ 1686 [13,14]
Median unit cost of emergency department visit
(interquartile range)
79 (55–158) QIP99
Mean unit cost of hospitalization 2203 [23]
Non–health care cost ($)
Transportation cost per visit or hospitalization 20 (10–40) Assumption
CI, confidence interval; RR, rate ratio relative to standard therapy group.
 Omalizumab add-on group indicates the total number of patients treated with omalizumab plus standard therapy.
y Responder subgroup indicates a subgroup of patients who derive great benefits from omalizumab plus standard therapy.
z Utility values inside and outside of parentheses are used as the primary utility set and the alternative utility set, respectively.
§ Omalizumab 75-mg vials are unavailable now in Japan and based on our assumption.
99 QIP indicates our department’s Quality Indicator/Improvement Project, which collects clinical and claims data from more than 200 hospitals in Japan.
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Table 1 shows symptom-free and exacerbation rates of the
standard therapy group and rate ratios for the omalizumab
add-on group and responder subgroup relative to the standard
therapy group. Confidence intervals of the rate ratio under log-
normal distribution were used as the range for probabilistic
sensitivity analysis. Utility values and asthma-related mortality
risks were shared among the two groups and the responder
subgroup (Table 1). Omalizumab cost, standard therapy cost, and
unit cost of health care resource use are also provided in Table 1.
The results of the base-case analysis with the primary utility
set are presented in Table 2. The mean lifetime discounted costs
and QALYs were $43,000 and 16.00, respectively, for the standard
therapy group and $114,100 and 16.10, respectively, for the
omalizumab add-on group. The results produced an ICER of
$755,200 per QALY, with the 95% CI ranging from $614,200 to
$1,298,500 for the base-case analysis of the omalizumab add-on
group relative to the standard therapy group.
In the base-case analysis with the alternative utility set, the
ICER was $633,500 (95% CI $515,300–$1,054,500) per QALY gained
(Table 2).
Sensitivity Analysis
A tornado diagram of one-way sensitivity analyses with the
primary utility set is shown in Fig. 2. The results indicate that
the ICER was sensitive to the risk of death from hospitalization
($550,700–$1,225,200), rate ratio for hospitalization ($678,500–
$1,143,400), utility for symptom-free asthma ($625,500–$1,042,200),
rate ratio for symptom-free asthma ($654,400–$878,400), discount
rate ($612,700–$826,500), utility for day-to-day asthma ($675,700–
$855,900), and omalizumab cost ($679,400–$755,200). The ICER
decreased by 10% when the omalizumab cost was reduced by
10%. Threshold analysis identified a break-even price of $40 for a
150-mg vial of omalizumab. In the subgroup analysis of patients
with particularly severe asthma, the ICER was $583,600 (95% CI
$462,300–$1,308,900) per QALY gained.
The cost-effectiveness acceptability curve illustrates the
cost-effectiveness probability of omalizumab over a range of
willingness-to-pay (WTP) values (Fig. 3). For a WTP threshold
value of $728,000, the cost-effectiveness probability of omalizu-
mab was 51%.
EVPI for Response to Omalizumab
In the responder subgroup analysis with the primary utility set,
the mean lifetime discounted costs and QALYs were $155,300
and 16.19, respectively, resulting in an ICER of $590,100 (95%
CI $430,700–$858,600) relative to the standard therapy group
(Table 2). The ICER (point estimate) for the responder subgroup
was 22% lower than that for the omalizumab add-on group (i.e.,
the base-case analysis).
In the value of information analysis with the primary utility
set, the individual EVPI was $4100 (95% CI $2500–$6000) at a
threshold value of $45,000 per QALY. The population EVPI for total
eligible patients with severe asthma (7200 patients) amounted to
$28 million (95% CI $17 million–$42 million) per year.T
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In the present study, we analyzed the cost-effectiveness of
omalizumab add-on therapy relative to standard therapy alone,
on the basis of clinical data from an RCT carried out in Japan. The
results showed that omalizumab was not cost-effective given the
existing evidence.
Fig. 2 – Tornado diagram summarizing one-way sensitivity analyses of the incremental cost-effectiveness ratio (cost per
quality-adjusted life-year) of omalizumab plus standard therapy relative to standard therapy alone. RR indicates rate ratio for
omalizumab plus standard therapy relative to standard therapy alone.
Fig. 3 – Cost-effectiveness acceptability curve. This graph illustrates the probability that a treatment strategy is cost-effective
over a range of willingness-to-pay thresholds for an additional quality-adjusted life-year.
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cost and that the cost-effectiveness was improved when omalizu-
mab add-on therapy was targeted at responders or patients with
particularly severe asthma. The best ways to improve the cost-
effectiveness of omalizumab may include decreasing the price
of omalizumab, restricting omalizumab therapy to a subgroup of
patients with a higher risk of exacerbation, which has been
recommended by the National Institute for Health and Clinical
Excellence [12], and confining the intervention to previously
predicted responders identified on the basis of pretreatment
patient characteristics. Further research should be performed on
omalizumab response prediction methods (e.g., genetic testing) to
help physicians decide whether to begin omalizumab add-on
therapy. The development of prediction methods for patients’
response to omalizumab will considerably improve the ICER. We
calculated the EVPI for omalizumab response to estimate the value
of further research for developing prediction methods, although
the estimation of EVPI is uncommon in economic evaluations in
which the ICER is far from the WTP threshold. Thus, caution is
required to assess the quantitative results, and further studies
should involve real testing value for responders. However, our
findings suggest the importance of prediction methods.
Dewilde et al. [7] and Brown et al. [8] demonstrated that
omalizumab therapy was cost-effective in patients with severeasthma. In contrast, Campbell et al. [9] presented an ICER of
$287,200 and $172,300 per QALY gained in the base-case analysis
and the responder scenario analysis (where nonresponders
remained and received 16-week omalizumab therapy), respec-
tively. Wu et al. [10] analyzed the relationship between HRQOL
and lung function parameters and concluded that omalizumab,
with an ICER of $821,000 per QALY gained, was not cost-effective.
One possible explanation for the inconsistency between the
results from the former three studies using Markov models and
the present study may be the difference in model structure.
Our model included the symptom-free state to distinguish non-
exacerbation utilities of the omalizumab add-on group from
those of the standard therapy group. Furthermore, there is a
difference in how asthma-related death is linked with other
states in the models. Campbell et al. [9], as in our study, linked
asthma-related death with the hospitalization state, whereas
Dewilde et al. [7] and Brown et al. [8] assumed that patients
transitioned from the severe exacerbation state to asthma-
related death at a 2.082% to 3.108% risk in their model, which
did not include the hospitalization state. Considering that severe
exacerbations were more frequent than hospitalizations, more
patients should have died from asthma in the models of Dewilde
et al. and Brown et al., compared with our model and that of
Campbell et al., thus creating a bias in favor of omalizumab.
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of omalizumab.Strengths and Limitations
Our study has several advantages compared with those reported
in the literature. To the best of our knowledge, the present study
is the first to explore the efficient use of omalizumab and assess
the value of further research to eliminate the uncertainty asso-
ciated with patients’ response to omalizumab. Another advan-
tage is the first economic evaluation using clinical and cost
outcomes of omalizumab from an Asian population. In Japan,
medical fees for health care services are relatively low among
Organisation for Economic Co-operation and Development coun-
tries [15]. Chronic diseases, such as asthma, that involve the
repeated use of urgent health care services underscore the
importance of conducting the economic evaluation of an expen-
sive drug in the Japanese setting.
Our analysis also has assumptions and limitations. First,
the input data for HRQOL utilities were derived from another
study conducted outside Japan. The generalizability of HRQOL in
asthmatic patients to other countries might be limited [18].
Considering this limitation, we presented the omalizumab-
favorable scenario in which the alternative utility set had a
broader utility range than that in previous studies, as recom-
mended in the practical guide for economic evaluations that
involve parameter uncertainties [29]. This means that our alter-
native utility set was the most favorable to omalizumab. Yet,
omalizumab was not cost-effective. These ensure that our find-
ings are rigorous. Second, our value of information analysis
was based on structural uncertainties. Experts have been advo-
cating how to handle this type of uncertainty [30]. There are,
however, limited examples of working on this issue in economic
evaluations of health interventions. Third, clinical data of the
response to omalizumab were not available from the RCT in
Japan. We advocate that data of responders should be collected
alongside further clinical trials. Finally, we extracted clinical
parameters of the overall patients treated with omalizumab
and omalizumab responders from different clinical trials to
estimate the EVPI for omalizumab response. Further research
exploring EVPI more precisely by using clinical data from a single
trial may be needed.Conclusions
We conclude that omalizumab is not cost-effective in Japan given
a WTP of $45,000 per QALY. Omalizumab, however, will remain in
the market because it possesses a unique mechanism of action
and provides great benefits to patients with severe asthma,
particularly responders. The cost-effectiveness of omalizumab
may be improved if omalizumab therapy could be confined to
previously predicted responders. Future studies to investigate
prediction methods for the identification of responders are of
great value. Caution, however, is required in interpreting the EVPI
for omalizumab response, given the assumptions and the struc-
tural uncertainties. We look forward to a reduction in the price of
omalizumab, which will improve cost-effectiveness.
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